Yea Christopher, Chief Development Officer at KalVista Pharmaceuticals ($KALV), sold shares on the open market 11 times over the past year, totaling about $830,000. His most recent sale occurred on February 23, 2026. These sales rank him 5,351st among 11,678 insiders in our database by total value sold, below the average of $8.6 million per insider and 6.4 transactions. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 22, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 231,048.0000 | 53,883,681 | 1.37% | 0.01% |
| Feb. 23, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 4347 | $15.57 | 226,701.0000 | 53,883,681 | 1.88% | 0.01% |
| Feb. 21, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3750 | $0.00 | 45,000.0000 | 53,883,681 | 7.69% | 0.01% |
| Feb. 22, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 28,125.0000 | 53,883,681 | 10.00% | 0.01% |
| Feb. 21, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3750 | $0.00 | 227,923.0000 | 53,883,681 | 1.67% | 0.01% |
| Feb. 17, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 1,774.0000 | 53,883,681 | 50.00% | 0.00% |
| Feb. 18, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1109 | $15.00 | 224,173.0000 | 53,883,681 | 0.49% | 0.00% |
| Feb. 17, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 1774 | $0.00 | 225,282.0000 | 53,883,681 | 0.79% | 0.00% |
| Nov. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 31,250.0000 | 53,883,681 | 9.09% | 0.01% |
| Nov. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3750 | $0.00 | 48,750.0000 | 53,883,681 | 7.14% | 0.01% |
| Nov. 24, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 4331 | $13.45 | 223,508.0000 | 53,883,681 | 1.90% | 0.01% |
| Nov. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 227,839.0000 | 53,883,681 | 1.39% | 0.01% |
| Nov. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3750 | $0.00 | 224,714.0000 | 53,883,681 | 1.70% | 0.01% |
| Nov. 20, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Employee Stock Option (Right to Buy) | 87390 | $0.00 | 0.0000 | 53,883,681 | 100.00% | 0.16% |
| Nov. 20, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 87390 | $0.00 | 220,964.0000 | 53,883,681 | 65.42% | 0.16% |
| Nov. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 3,548.0000 | 53,883,681 | 33.33% | 0.00% |
| Nov. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 4205 | $0.00 | 136,257.0000 | 53,883,681 | 3.18% | 0.01% |
| Nov. 18, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2683 | $14.48 | 133,574.0000 | 53,883,681 | 1.97% | 0.00% |
| Nov. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2431 | $0.00 | 0.0000 | 53,883,681 | 100.00% | 0.00% |
| Aug. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 134,006.0000 | 49,652,878 | 2.39% | 0.01% |
| Aug. 25, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1954 | $13.42 | 132,052.0000 | 49,652,878 | 1.46% | 0.00% |
| Aug. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 34,375.0000 | 49,652,878 | 8.33% | 0.01% |
| Aug. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3750 | $0.00 | 133,243.0000 | 49,652,878 | 2.90% | 0.01% |
| Aug. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3750 | $0.00 | 52,500.0000 | 49,652,878 | 6.67% | 0.01% |
| Aug. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2362 | $13.22 | 130,881.0000 | 49,652,878 | 1.77% | 0.00% |
| Aug. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 4203 | $0.00 | 132,142.0000 | 49,652,878 | 3.29% | 0.01% |
| Aug. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1773 | $0.00 | 5,322.0000 | 49,652,878 | 24.99% | 0.00% |
| Aug. 18, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2649 | $13.19 | 129,493.0000 | 49,652,878 | 2.00% | 0.01% |
| Aug. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2430 | $0.00 | 2,431.0000 | 49,652,878 | 49.99% | 0.00% |
| July 8, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | A | Common Stock | 60000 | $0.00 | 158,189.0000 | 49,652,878 | 61.11% | 0.12% |
| July 9, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 30250 | $15.69 | 127,939.0000 | 49,652,878 | 19.12% | 0.06% |
| May 23, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1926 | $11.31 | 98,189.0000 | 49,652,878 | 1.92% | 0.00% |
| May 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 100,115.0000 | 49,652,878 | 3.22% | 0.01% |
| May 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 37,500.0000 | 49,652,878 | 7.69% | 0.01% |
| May 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3750 | $0.00 | 56,250.0000 | 49,652,878 | 6.25% | 0.01% |
| May 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2317 | $11.88 | 96,990.0000 | 49,652,878 | 2.33% | 0.00% |
| May 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3750 | $0.00 | 99,307.0000 | 49,652,878 | 3.92% | 0.01% |
| May 19, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2600 | $11.84 | 95,557.0000 | 49,652,878 | 2.65% | 0.01% |
| May 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 4205 | $0.00 | 98,157.0000 | 49,652,878 | 4.48% | 0.01% |
| May 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 7,095.0000 | 49,652,878 | 20.00% | 0.00% |
| May 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2431 | $0.00 | 4,861.0000 | 49,652,878 | 33.34% | 0.00% |
| Feb. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | A | Restricted Stock Unit | 60000 | $0.00 | 60,000.0000 | 46,590,154 | 9999.99% | 0.13% |
| Feb. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 95,870.0000 | 46,590,154 | 3.37% | 0.01% |
| Feb. 22, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 40,625.0000 | 46,590,154 | 7.14% | 0.01% |
| Feb. 24, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1918 | $10.02 | 93,952.0000 | 46,590,154 | 2.00% | 0.00% |
| Feb. 18, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 2601 | $9.82 | 92,745.0000 | 46,590,154 | 2.73% | 0.01% |
| Feb. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2430 | $0.00 | 7,292.0000 | 46,590,154 | 24.99% | 0.01% |
| Feb. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 8,869.0000 | 46,590,154 | 16.67% | 0.00% |
| Feb. 17, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 4204 | $0.00 | 95,346.0000 | 46,590,154 | 4.61% | 0.01% |
| Nov. 26, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1963 | $9.87 | 91,142.0000 | 46,590,154 | 2.11% | 0.00% |
| Nov. 22, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 43,750.0000 | 46,590,154 | 6.67% | 0.01% |
| Nov. 22, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 93,105.0000 | 46,590,154 | 3.47% | 0.01% |
| Nov. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 10,643.0000 | 46,590,154 | 14.29% | 0.00% |
| Nov. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7291 | $0.00 | 0.0000 | 46,590,154 | 100.00% | 0.02% |
| Nov. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2431 | $0.00 | 9,722.0000 | 46,590,154 | 20.00% | 0.01% |
| Nov. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 11496 | $0.00 | 97,172.0000 | 46,590,154 | 13.42% | 0.02% |
| Nov. 18, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 7192 | $9.26 | 89,980.0000 | 46,590,154 | 7.40% | 0.02% |
| Aug. 23, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 1916 | $12.40 | 85,676.0000 | 36,786,575 | 2.19% | 0.01% |
| Aug. 22, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 3125 | $0.00 | 87,592.0000 | 36,786,575 | 3.70% | 0.01% |
| Aug. 22, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 3125 | $0.00 | 46,875.0000 | 36,786,575 | 6.25% | 0.01% |
| Aug. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2430 | $0.00 | 12,153.0000 | 36,786,575 | 16.66% | 0.01% |
| Aug. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 11495 | $0.00 | 91,569.0000 | 36,786,575 | 14.36% | 0.03% |
| Aug. 19, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 7102 | $12.01 | 84,467.0000 | 36,786,575 | 7.76% | 0.02% |
| Aug. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1773 | $0.00 | 12,417.0000 | 36,786,575 | 12.49% | 0.00% |
| Aug. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7292 | $0.00 | 7,291.0000 | 36,786,575 | 50.00% | 0.02% |
| May 22, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | A | Restricted Stock Units | 50000 | $0.00 | 50,000.0000 | 36,786,575 | 9999.99% | 0.14% |
| May 20, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 11610 | $11.76 | 80,074.0000 | 36,786,575 | 12.66% | 0.03% |
| May 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 18789 | $0.00 | 91,684.0000 | 36,786,575 | 25.78% | 0.05% |
| May 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 14,190.0000 | 36,786,575 | 11.11% | 0.00% |
| May 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7292 | $0.00 | 14,583.0000 | 36,786,575 | 33.33% | 0.02% |
| May 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7292 | $0.00 | 0.0000 | 36,786,575 | 100.00% | 0.02% |
| May 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2431 | $0.00 | 14,583.0000 | 36,786,575 | 14.29% | 0.01% |
| Feb. 20, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 12053 | $14.11 | 72,895.0000 | 0 | 14.19% | 0.00% |
| Feb. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7292 | $0.00 | 29,167.0000 | 0 | 20.00% | 0.00% |
| Feb. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Performance Stock Units | 7292 | $0.00 | 7,292.0000 | 0 | 50.00% | 0.00% |
| Feb. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Common Stock | 18788 | $0.00 | 84,948.0000 | 0 | 28.40% | 0.00% |
| Feb. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 2430 | $0.00 | 17,014.0000 | 0 | 12.50% | 0.00% |
| Feb. 17, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | Restricted Stock Unit | 1774 | $0.00 | 15,964.0000 | 0 | 10.00% | 0.00% |
| Feb. 14, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 39886 | $15.01 | 66,160.0000 | 0 | 37.61% | 0.00% |
| Feb. 11, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | A | Performance Stock Units | 29167 | $0.00 | 29,167.0000 | 0 | 9999.99% | 0.00% |
| Feb. 11, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | CHIEF DEVELOPMENT OFFICER | A | Common Stock | 60000 | $0.00 | 106,046.0000 | 0 | 130.30% | 0.00% |
| Nov. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Performance Stock Unit | 7292 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Common Stock | 11497 | $0.00 | 53,159.0000 | 0 | 27.60% | 0.00% |
| Nov. 20, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | S | Common Stock | 7113 | $8.23 | 46,046.0000 | 0 | 13.38% | 0.00% |
| Nov. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 1774 | $0.00 | 17,738.0000 | 0 | 9.09% | 0.00% |
| Nov. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 2431 | $0.00 | 19,444.0000 | 0 | 11.11% | 0.00% |
| Aug. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Common Stock | 11494 | $0.00 | 48,804.0000 | 0 | 30.81% | 0.00% |
| Aug. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Performance Stock Unit | 7291 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 2430 | $0.00 | 21,875.0000 | 0 | 10.00% | 0.00% |
| Aug. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 1773 | $0.00 | 19,512.0000 | 0 | 8.33% | 0.00% |
| Aug. 18, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | S | Common Stock | 7142 | $10.73 | 41,662.0000 | 0 | 14.63% | 0.00% |
| Feb. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 2430 | $0.00 | 26,736.0000 | 0 | 8.33% | 0.00% |
| May 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Common Stock | 4205 | $0.00 | 39,914.0000 | 0 | 11.78% | 0.00% |
| May 18, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | S | Common Stock | 2604 | $10.14 | 37,310.0000 | 0 | 6.52% | 0.00% |
| Jan. 11, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | A | Restricted Stock Unit | 29166 | $0.00 | 29,166.0000 | 0 | 9999.99% | 0.00% |
| May 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 2431 | $0.00 | 24,305.0000 | 0 | 9.09% | 0.00% |
| May 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 1774 | $0.00 | 21,285.0000 | 0 | 7.69% | 0.00% |
| Feb. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Common Stock | 4204 | $0.00 | 38,436.0000 | 0 | 12.28% | 0.00% |
| Feb. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | S | Common Stock | 2727 | $7.66 | 35,709.0000 | 0 | 7.09% | 0.00% |
| Feb. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Performance Restricted Stock Unit | 2430 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 17, 2023 | KalVista Pharmaceuticals, Inc. | $KALV | Yea Christopher | Chief Development Officer | M | Restricted Stock Unit | 1774 | $0.00 | 23,059.0000 | 0 | 7.14% | 0.00% |